Cystic Fibrosis Clinical Trial
Official title:
Long Term Safety and Tolerability Study of Open-Label Liposomal Amikacin for Inhalation (ARIKACE™) in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa
Verified date | June 2020 |
Source | Insmed Incorporated |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the long term safety and tolerability of Liposomal Amikacin for Inhalation (LAI) 590 mg once daily (QD) in Cystic Fibrosis patients with chronic infection due to pseudomonas aeruginosa. This long-term, open-label, multi-cycle extension study enrolled subjects who had successfully completed study TR02-108, were compliant with the study protocol, and did not meet any of the listed study discontinuation criteria. The safety and tolerability of LAI were evaluated for up to approximately 2 years.
Status | Completed |
Enrollment | 206 |
Est. completion date | July 16, 2015 |
Est. primary completion date | July 16, 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years and older |
Eligibility |
Key Inclusion Criteria: - Written informed consent or assent - Subject has completed study TR02-108, and has been compliant with the study protocol - Women of childbearing potential must agree to use reliable methods of contraception for the duration of the study Key Exclusion Criteria: - Subject met any of the listed criteria for study drug discontinuation in protocol TR02-108. - Abnormal laboratory assessments including LFT (= 3× upper limit of normal [ULN]), serum creatinine (> 2× ULN) and absolute neutrophil count [ANC] (< 1000). - Psychotic, addictive or other disorder limiting the ability to provide informed consent or to comply with study requirements. - History of alcohol, medication or illicit drug abuse within the 6 months prior to consent. - Smoking tobacco or any substance within 6 months prior to consent or anticipated inability to refrain from smoking throughout the study |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Insmed Incorporated |
Austria, Belgium, Bulgaria, Canada, Denmark, France, Germany, Greece, Hungary, Ireland, Italy, Netherlands, Poland, Serbia, Slovakia, Spain, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Treatment Emergent Adverse Events (TEAEs) up to Day 672 | Treatment emergent adverse events including serious adverse events (SAE) and adverse events (AE) leading to permanent discontinuation of study drug | From Study Initiation up to Day 672 | |
Primary | Laboratory Abnormalities up to Day 672 | Number of Subjects with Grade 3 or Higher Abnormalities in Clinical Laboratory Values Number of Subjects with Grade 3 or Higher Hematology Laboratory Value Abnormalities Number of Subjects with Grade 3 or Higher Chemistry Laboratory Value Abnormalities |
Baseline, Day 377 and Day 672 | |
Primary | Acute Tolerability as Measured by Pulmonary Function Test (PFT) Changes Pre to Post Dose | Number of Subjects with a >15% in Decline in Forced Expiratory Volume in 1 Second (FEV1) From Predose to Postdose | Day 1, Day 84, Day 196, Day 281, Day 337, Day 449, Day 532 and Day 644 | |
Primary | Respiratory Rate: Change From Baseline to Day 672 | Respiratory rate was recorded at every visit as per standard practice at each investigational site. | From Study Initiation up to Day 672 | |
Primary | Heart Rate: Change From Baseline From Day 672 | Pulse rate (after at least 5-minute rest) was recorded at every visit as per standard practice at each investigational site. | From Study Initiation up to Day 672 | |
Primary | Systolic BP: Change From Baseline at Day 672 | Sitting blood pressure was recorded at every visit as per standard practice at each investigational site. | From Study Initiation up to Day 672 | |
Primary | Diastolic BP: Change From Baseline at Day 672 | Sitting blood pressure was recorded at every visit as per standard practice at each investigational site. | From Study Initiation up to Day 672 | |
Primary | Body Temperature: Change From Baseline at Day 672 | Body temperature was recorded at every visit as per standard practice at each investigational site. | From Study Initiation up to Day 672 | |
Primary | Oxygen Saturation: Change From Baseline at Day 672 | Change in oxygen saturation as measured with pulse oximetry was performed via finger probes placed on the extremity opposite arterial lines and noninvasive blood pressure monitoring devices so that pulsatile flow was not interrupted. | From Study Initiation up to Day 672 | |
Primary | Minimum Inhibitory Concentrations (MICs) for Pseudomonas Aeruginosa (Pa) and Burkholderia Species From Day 1 to Days 169, 337, 505 and 672 | Sputum was cultured for quantitative microbiological evaluation of Pa and Burkholderia species in designated regional central microbiology laboratories. A standard microbiology protocol was used for Pa culture and identification for each morphologically distinct Pa phenotype. Although planned in the Statistical Analysis Plan (SAP), MICs of amikacin Burkholderia species were not determined due to the small number of isolates with Burkholderia. In addition, susceptibility testing of isolates of Pa and Burkholderia species against a panel of commonly used antipseudomonal antibiotics was planned but was not performed. The results of the following analyses for Pa isolates are presented. Frequency of MIC of Amikacin Frequency of MIC of Tobramycin MIC50: lowest concentration of the antibiotic at which 50 % of the isolates were inhibited. |
Day 1, Day 169, Day 337, Day 505 and Day 672 | |
Primary | Evaluation of Audiology | Hearing was evaluated using air conduction [AC]. Bone conduction was required if the AC testing demonstrated a decrease of >20 decibels [dB]. Hearing loss was categorized using Common Terminology Criteria for Adverse Events as follows: GRADE 1 (best): Adults [A] on a Monitoring Program [MP]: Threshold shift of 15-25 dB; Pediatric [P]: Threshold shift >20 dB at 8 kilohertz (kHz). GRADE 2: [A] on a MP: Threshold shift of >25 dB; [A] not enrolled in MP: hearing loss; hearing aid/intervention not indicated; [P]: Threshold shift >20 dB at 4 kHz and above. GRADE 3: [A] enrolled in MP: Threshold shift of >25 dB; therapeutic intervention indicated; [A]: Not enrolled in MP: hearing aid/intervention; [P]: therapeutic intervention, including hearing aids: Threshold shift >20 dB at 3 kHz and above; additional speech-language related services. GRADE 4 (worst): [A]: Profound bilateral hearing loss; non-serviceable hearing; [P]: cochlear implant & additional speech-language related services. | Day 337 and Day 672 | |
Primary | Change in Serum Creatinine Throughout the Study | Common Terminology Criteria for Adverse Events (CTCAE) Grade 1: > ULN-1.5 × ULN CTCAE Grade 2: > 1.5 × ULN to 3.0 x ULN |
Baseline, Day 337 and Day 672 | |
Secondary | Percent Change in FEV1 Throughout the Study | Percent Change From Baseline in Predose FEV1 | Baseline, Day 337 and Day 672 | |
Secondary | Number of Subjects Experiencing a Protocol Defined Pulmonary Exacerbation | For number of subjects to first protocol-defined pulmonary exacerbation, follow-up time began at the first dose of study drug (Day 1) and ended no later than Day 700 (28-day follow up). | From Study Initiation up to Day 700 | |
Secondary | Number of Subjects Initiating Treatment. | The number of subjects initiating antipseudomonal therapy for protocol-defined pulmonary exacerbation confirmed by the investigator, and for investigator-defined pulmonary exacerbation were summarized. The data presented below is the Frequency of Systemic or Inhaled Antipseudomonal Therapy for Protocol-defined Pulmonary Exacerbations Confirmed by Investigator - Time to First Use of Any New Antibiotic Treatment, Censoring at Date of Last Contact |
From Study Initiation up to Day 672 | |
Secondary | Number of Participants Who Received Antipseudomonal Antibiotic Treatment for Protocol Defined Pulmonary Exacerbation | From Study Initiation up to Day 700 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04696198 -
Thoracic Mobility in Cystic Fibrosis Care
|
N/A | |
Completed |
NCT00803205 -
Study of Ataluren (PTC124™) in Cystic Fibrosis
|
Phase 3 | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03601637 -
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
|
Phase 3 | |
Terminated |
NCT02769637 -
Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
|
||
Recruiting |
NCT06032273 -
Lung Transplant READY CF 2: CARING CF Ancillary RCT
|
N/A | |
Recruiting |
NCT06012084 -
The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis
|
N/A | |
Recruiting |
NCT06030206 -
Lung Transplant READY CF 2: A Multi-site RCT
|
N/A | |
Recruiting |
NCT05392855 -
Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)
|
N/A | |
Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
Recruiting |
NCT04039087 -
Sildenafil Exercise: Role of PDE5 Inhibition
|
Phase 2/Phase 3 | |
Recruiting |
NCT04056702 -
Impact of Triple Combination CFTR Therapy on Sinus Disease.
|
||
Completed |
NCT04058548 -
Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation
|
N/A | |
Completed |
NCT04038710 -
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
|
||
Completed |
NCT03637504 -
Feasibility of a Mobile Medication Plan Application in CF Patient Care
|
N/A | |
Recruiting |
NCT03506061 -
Trikafta in Cystic Fibrosis Patients
|
Phase 2 | |
Completed |
NCT03566550 -
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
|
||
Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
Recruiting |
NCT04010253 -
Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis
|
N/A |